rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NeuroSense Therapeutics Ltd. -

NRSN · Nasdaq

Health CareBiotechnologyNot moving yet

NRSN stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 74.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$800K
Insider sales, 12 months
$0
Officials’ trades on record
2
Institutions holding
11 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$771KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 0, Senate 0, executive 2; 1 people.

WhoDidAmountTraded
Lee M. Zeldin Executive branch: Office of Government EthicsEnvironmental Protection Agencybought$1k–$15k1 Aug 2025filed 18 Nov 2025
Lee M. Zeldin Executive branch: Office of Government EthicsEnvironmental Protection Agencysold$1k–$15k13 May 2025filed 15 Jul 2025

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Or EisenbergChief Financial Officerbought250,000at $0.8016 Jun 2026filed 17 Jun 2026
Alon Ben-NoonChief Executive Officerbought250,000at $0.8016 Jun 2026filed 17 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders11-2 on the quarter
New · exited1 · 3
Reported value$279K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
UBS Group AGadded · filed 13 Aug 2026108,636$78K+59,540+121.3%
Independent Advisor Allianceadded · filed 12 Aug 2026100,000$72K+50,000+100.0%
Yorkville Advisors Global, LPunchanged · filed 6 Aug 202678,000$56K00.0%
COMMONWEALTH EQUITY SERVICES, LLCunchanged · filed 29 Jul 202622,775$16K00.0%
PNC Financial Services Group, Inc.unchanged · filed 7 Aug 202621,150$15K00.0%
Pathstone Holdings, LLCunchanged · filed 13 Aug 202616,528$12K00.0%
GEODE CAPITAL MANAGEMENT, LLCunchanged · filed 12 Aug 202615,870$11K00.0%
XTX Topco Ltdnew · filed 14 Aug 202611,473$8,261+11,473
Creative Planningreduced · filed 13 Aug 202611,410$8,215-501−4.2%
JONES FINANCIAL COMPANIES LLLPunchanged · filed 14 Aug 20261,000$75700.0%
31 Mar 2023 – 30 Jun 2026
4914Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Alon Ben-Noon Company insiderChief Executive Officer · last 16 Jun 20261 · 0
Or Eisenberg Company insiderChief Financial Officer · last 16 Jun 20261 · 0
Hagit Binder Company insiderGeneral Manager · last 26 Mar 20260 · 0
Niva Russek-Blum Company insiderChief Technology Officer · last 26 Mar 20260 · 0
Lee M. Zeldin Executive branchEnvironmental Protection Agency · last 1 Aug 20251 · 1

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 202540.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$166K
Free cash flowFY 2025 · to 31 Dec 2025−$7.7M

Analyst forecasts

No analyst forecasts yet.